Benjamin P. Levy, MD: The REVEL trial looked at adding ramucirumab to docetaxel compared with docetaxel alone for patients with stage 4 adenocarcinoma or squamous cell histology, who had progressed on platinum chemotherapy. Some of these patients received maintenance if they were doing well, but this a second-line trial. Importantly, in the frontline setting, a percentage of the patients had received bevacizumab. Those patients still garnered a benefit with ramucirumab added to docetaxel.
In this trial, the bottom line was that adding ramucirumab to docetaxel improved response rate, progression-free survival, and overall survival. I would make the argument that we’ve tried, very hard, to add novel agents to docetaxel to try to get a survival advantage. We have failed, a large percentage of the time. This was one of those few exceptions, where adding ramucirumab, an antiangiogenic drug, to a docetaxel backbone improved survival.
I would argue that any survival advantage is meaningful. Does that mean that every patient who’s on platinum-doublet chemotherapy, who progresses, gets docetaxel with ramucirumab? No. But given that we now have immunotherapy moving upfront with chemotherapy, I do think we need to look hard, to really try to generate some data to see how docetaxel/ramucirumab performs in these patients. Outside of the clinical trial, I think that this is kind of my de facto regimen, if they can tolerate it.
I think patients need to be exposed to every single drug possible in a short amount of time, especially if their tumors are growing rapidly. This is a regimen that should be considered for patients who are progressing on platinum-doublet therapy.
We need to keep in mind that the REVEL trial included both adenocarcinoma and squamous cell patients. Both of these patient populations, if they are progressing on a platinum-doublet regimen, are candidates for ramucirumab with docetaxel. For both of these patient populations, if they are progressing on a platinum-doublet therapy with or without immunotherapy, I will consider using the doublet for a fit patient. If they’re not fit, maybe I won’t add the ramucirumab. But if they’re fit and motivated, then I try.
The question becomes, if you haven’t used immunotherapy with chemotherapy upfront, and you’ve instead used it as a second-line option, what do you do in the third-line setting? This is where things get a little tricky. The docetaxel/ramucirumab regimen really just looked at the second-line setting. For patients who start out on carboplatin/pemetrexed, who then go on to receive immunotherapy, what do you do as third-line therapy? That patient population may be a little harder to deliver ramucirumab with docetaxel in, but it’s something that I try to do if they’re fit. I may move, at that point, to a weekly docetaxel regimen with ramucirumab, but I wouldn’t not consider it just because we’re at the third-line rather than second-line setting. I try to give the best drugs to the patient that I know work at the line of therapy in which they need it.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More